Inhibiting Amyloid-Beta Peptide/Rage Interaction At The Blood-Brain Barrier

摘要

Small molecules are used to inhibit specific receptor-ligand interaction between Alzheimer's amyloid-&bgr; peptide (A&bgr;) and Receptor for Advanced Gly-cation Endproducts (RAGE). Objectives include treating Alzheimer's disease and other pathologies involving cerebral amyloid angiopathy; improving blood flow to or within the brain; decreasing the level of A&bgr; in the brain; reducing neuropathology associated with Alzheimer's disease; reducing inflammation and/or oxidant stress in the brain; improving memory and/or learning; treating other conditions involving A&bgr;/RAGE interaction at the blood-brain barrier, RAGE-mediated transport of A&bgr; into the brain, or RAGE activation in brain vasculature and/or brain parenchyma (e.g., diabetic complications); or any combination thereof.